Pharmacogenetics

Effectiveness of treatment with PEG-interferon and Ribavirin drugs

Efficacy of therapy with "Clopidogrel" ("Plavix")

Genodiagnostics of Resistance to Hepatitis C Therapy, Types 1a, 1b, 3 (NS3, NS5A, NS5B)

Assessment of the effect of CYP2D6 and CYP2C19 on the metabolism of serotonin/norepinephrine reuptake inhibitor antidepressants (escitalopram, citalopram, sertraline, fluvoxamine, paroxetine, venlafaxine)

Efficacy of therapy with "Clopidogrel", extended (CYP2C19*2, *3, *17)

DPYD Genotyping for Chemotherapy Toxicity Assessment (DPYD*2A (c.1905+1G>A), DPYD *13 (c.1679T>G; p.Ile560Ser), c.2846A>T (p.Asp949Val) and HapB3 (c.1129–5923C>G)

Assessment of the effect of CYP2D6 and CYP2C19 on the metabolism of tricyclic antidepressants – amitriptyline, nortriptyline, desipramine, doxepin, imipramine, trimipramine

Pharmacogenetics of adverse effects of allopurinol therapy (HLA-B*58:01 gene)

Determination of the biologically optimal dose of warfarin

Cytochrome P450 1A2 gene. Genotyping for the CYP1A2 (c.-163C>A) marker